- Home
- EFR vs ACIU Comparison
EFR vs ACIU Comparison
Compare EFR & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EFR
- ACIU
- Stock Information
- Founded
- EFR 2003
- ACIU 2003
- Country
- EFR United States
- ACIU Switzerland
- Employees
- EFR N/A
- ACIU N/A
- Industry
- EFR Trusts Except Educational Religious and Charitable
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- EFR Finance
- ACIU Health Care
- Exchange
- EFR Nasdaq
- ACIU Nasdaq
- Market Cap
- EFR 372.9M
- ACIU 305.7M
- IPO Year
- EFR N/A
- ACIU 2016
- Fundamental
- Price
- EFR $12.89
- ACIU $3.27
- Analyst Decision
- EFR
- ACIU Strong Buy
- Analyst Count
- EFR 0
- ACIU 2
- Target Price
- EFR N/A
- ACIU $12.00
- AVG Volume (30 Days)
- EFR 88.6K
- ACIU 86.5K
- Earning Date
- EFR 01-01-0001
- ACIU 11-05-2024
- Dividend Yield
- EFR 9.43%
- ACIU N/A
- EPS Growth
- EFR N/A
- ACIU N/A
- EPS
- EFR 1.69
- ACIU N/A
- Revenue
- EFR N/A
- ACIU $48,505,404.00
- Revenue This Year
- EFR N/A
- ACIU N/A
- Revenue Next Year
- EFR N/A
- ACIU $938.44
- P/E Ratio
- EFR $7.74
- ACIU N/A
- Revenue Growth
- EFR N/A
- ACIU 4097200.00
- 52 Week Low
- EFR $10.95
- ACIU $2.25
- 52 Week High
- EFR $13.29
- ACIU $5.14
- Technical
- Relative Strength Index (RSI)
- EFR 60.77
- ACIU 54.36
- Support Level
- EFR $12.70
- ACIU $2.80
- Resistance Level
- EFR $12.84
- ACIU $3.12
- Average True Range (ATR)
- EFR 0.09
- ACIU 0.17
- MACD
- EFR 0.01
- ACIU 0.03
- Stochastic Oscillator
- EFR 97.73
- ACIU 97.92
About EFR Eaton Vance Senior Floating-Rate Fund of Beneficial Interest
Eaton Vance Senior Floating Rate Trust is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income. As a secondary objective, the fund intends to seek capital preservation. Its portfolio of investments consists of health care, industrial equipment, lodging and casinos, oil and gas, publishing, radio and television, telecommunications, and other areas. The trust invests in below investment grade floating rate loans, which are considered speculative because of the credit risk of their issuers.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.